Last year, Gilead Sciences paid $125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment for approval and lining up for a truncated regulatory process.

…read more

Source: Gilead takes a $125M FDA shortcut with its latest HIV combo


0 No comments